Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland

Table 1 Baseline characteristics of the audit sample (n = 30)

Variable	Mean	SD
Age (yr)	13.45	1.23
Duration of antipsychotic use (mo)	15.67	1.98
Average number of clinical reviews	3.43	0.46
Variable	n	%
Age groups (yr)
12-17	17	56.67
< 12	13	43.33
Gender
Male	28	93.33
Female	2	6.67
Antipsychotic
Risperidone	23	76.67
Aripiprazole	7	23.33
Psychiatric diagnosis
ADHD	12	40.00
ASD	4	13.33
ADHD + ASD	6	20.00
ADHD + other diagnosis	6	20.00
ASD + other diagnosis	2	6.67

ADHD: Attention deficit hyperactivity disorder; ASD: Autism spectrum disorder.

Table 2 Factors associated with likelihood of testing

Age groups (yr)	Total number	Number monitored
12-17	17	12
< 12	13	5
Antipsychotic
Risperidone	23	13
Aripiprazole	7	4
Psychiatric diagnosis
ADHD	12	7
ASD	4	2
ADHD + ASD	6	3
ADHD + other diagnosis	6	4
ASD + other diagnosis	2	1
Average duration of antipsychotic use	Mean	SD
Group A1	15.98	1.21
Group B2	15.42	1.32
Average number of clinical reviews	Mean	SD
Group A1	3.52	0.32
Group B2	3.31	0.36

¹Group A: Group that completed physical health monitoring requirements according to National Institute for Clinical Excellence (NICE) guidelines;

²Group B: Group that did not complete physical health monitoring requirements according to NICE guidelines. ADHD: Attention deficit hyperactivity disorder; ASD: Autism spectrum disorder.